-
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22 Apr 2025 10:55 GMT
… (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … mortality. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22 Apr 2025 11:03 GMT
… . Additional information relating to Arch Biopartners Inc., including our most recent …
-
LOUD Ventures and Persephoni BioPartners LLC Announce Strategic Partnership to Transform Therapeutic Innovation
15 Apr 2025 10:00 GMT
… , and operational expertise, and Persephoni BioPartners LLC, a venture studio advancing …
-
Panthera Biopartners Secures £20m In New Clinical Trials
18 Mar 2025 02:21 GMT
business
Image by Konstantin Kolosov from Pixabay
Panthera, the UK’s largest Site Management Organisation (SMO) with a clinical research site in York, has signed two clinical trial contracts worth over £10 million each. These trials, for international …
-
Arch Biopartners Closes Non-Brokered Private Placement
14 Mar 2025 20:30 GMT
… 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the … disclosed. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Closes Non-Brokered Private Placement
14 Mar 2025 20:41 GMT
… 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the … disclosed.
About Arch Biopartners
Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Arranges Non-Brokered Private Placement
05 Mar 2025 12:23 GMT
… 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the … disclosed. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)
18 Feb 2025 12:05 GMT
… Richard Muruve, CEO, Arch Biopartners “Congratulations to the PONTiAK … AKI. About Arch Biopartners Arch Biopartners Inc. is a … more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
08 Jan 2025 12:25 GMT
… 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the … Company. About Arch Biopartners Arch Biopartners Inc. is a … For more information on Arch Biopartners’ science and drug platform … information relating to Arch Biopartners Inc., including our most …
-
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
13 Nov 2024 06:14 GMT
Arch Biopartners Inc, a late-stage … said Richard Muruve, CEO, Arch Biopartners.
The cardiac surgery-associated acute … survival.
LSALT peptide is Arch Biopartners’ lead drug candidate for … the scientific rationale for Arch Biopartners’ to use LSALT peptide …
About
© 1995-2025